Wipro GE Healthcare bets on India’s medtech growth with INR 8000 Cr investment
Wipro GE Healthcare, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, is making a significant investment of over INR8000 Crores in manufacturing output and local R&D over the next five years.
According to the company, this investment aims to strengthen its local manufacturing footprint to cater to the growing domestic and international market demand in the medical technology sector. As part of this initiative, Wipro GE Healthcare will export its ‘Made in India’ PET CT Discovery IQ to 15 countries and manufacture other products like Revolution Aspire CT, Revolution ACT, and MR breast coils ‘In India for the World’.
India is identified as one of the top 20 global markets for medical devices, and Wipro GE Healthcare has been a pioneer in the ‘Make in India’ initiative for over three decades, investing significantly in R&D and manufacturing output.
Azim Premji, Chairman of Wipro GE Healthcare, highlighted India’s potential in the healthcare industry and the MedTech sector and emphasized the company’s commitment to localization. Peter J. Arduini, President and CEO of GE HealthCare, reiterated the importance of India as a priority market and the company’s dedication to expanding domestic capabilities and global footprint in MedTech manufacturing and R&D. Chaitanya Sarawate, Managing Director of Wipro GE Healthcare, emphasized the company’s focus on innovation and manufacturing in India for both domestic and global markets, aligning with India’s vision to become a key player in the global healthcare supply chain and manufacturing hub.
Category: Features, Technology & Devices
